Related Experiment Video
Updated: Jun 17, 2026
08:13
Microwave-driven Synthesis of Iron Oxide Nanoparticles for Fast Detection of Atherosclerosis
Published on: March 22, 2016
10.7K
ROS-Response Nanoparticles for Edaravone Delivery: Pathological-Activated Neuroprotection Against
Yi Zhou1, Fengjiao Chen2, Yutao Lin1
1Translational Medicine Center of Pain, Emotion and Cognition, Health Science Center, Ningbo University, Zhejiang, 315211, China.
Advanced Healthcare Materials
|July 8, 2025
Summary
A novel nanoparticle system, DEX-CDIPBE-ED, selectively releases edaravone to combat ischemic stroke. This targeted therapy reduces oxidative stress and neuroinflammation, offering enhanced neuroprotection with fewer side effects.
Area of Science:
- Neuroscience
- Biomedical Engineering
- Pharmacology
Background:
- Ischemic stroke causes significant mortality and disability, with reperfusion injury worsening neuronal damage via reactive oxygen species (ROS).
- Edaravone, a free radical scavenger, treats ischemic stroke but its broad ROS inhibition limits efficacy.
- Developing targeted therapies is crucial to mitigate ROS-induced damage in ischemic stroke.
Purpose of the Study:
- To develop a ROS-responsive nanoparticle system (DEX-CDIPBE-ED) for targeted edaravone delivery.
- To evaluate the efficacy of DEX-CDIPBE-ED in mitigating oxidative stress and neuroinflammation in ischemic stroke models.
- To compare the neuroprotective potential of DEX-CDIPBE-ED with free edaravone.
Main Methods:
- Fabrication of edaravone-loaded DEX-CDIPBE nanoparticles (DEX-CDIPBE-ED).
- In vitro assessment of antioxidant and neuroprotective effects in neuronal cells.
- In vivo evaluation in middle cerebral artery occlusion/reperfusion (MCAO/R) rat models, assessing behavioral deficits, oxidative stress, and neuroinflammation.
Main Results:
- DEX-CDIPBE-ED demonstrated potent antioxidant and neuroprotective effects in vitro.
- In MCAO/R rats, DEX-CDIPBE-ED significantly prevented behavioral deficits.
- DEX-CDIPBE-ED exhibited superior efficacy in reducing oxidative stress and neuroinflammation compared to edaravone in the ischemic penumbra.
Conclusions:
- DEX-CDIPBE-ED offers a promising ROS-responsive drug delivery system for ischemic stroke.
- Targeted edaravone release enhances neuroprotection while minimizing systemic toxicity.
- This approach represents a potential advancement in antioxidative therapy for ischemic stroke.
Related Concept Videos
01:15Ischemic Stroke l: Introduction
Ischemic stroke is an acute cerebrovascular condition in which blood flow to a brain region is suddenly interrupted, leading to tissue infarction. Neurons depend on continuous oxygen and glucose supply, so even brief reductions in perfusion cause energy failure, ionic imbalance, and irreversible injury. Ischemic strokes are classified into thrombotic and embolic types based on their underlying mechanisms.Thrombotic MechanismsThrombotic stroke develops when a clot forms within a cerebral artery.
01:15Ischemic Stroke ll: Pathophysiology
An ischemic stroke occurs when a cerebral blood vessel becomes obstructed, most often by a thrombus or embolus, interrupting the delivery of oxygen and glucose to brain tissue. Because neurons rely on continuous aerobic metabolism, energy failure begins within minutes of reduced perfusion. The region receiving the least blood flow becomes the infarct core, an area of irreversible cellular death. Surrounding this core lies the penumbra, a zone of hypoperfused but still viable tissue that is...